	Krystexxa (pegloticase)
BILLING CODE	J2507
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Office/Outpatient
STATUS	Prior Authorization Required

Krystexxa (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. According to the American College of Rheumatology guideline for management of gout, pegloticase should not be a first-line therapy. Pegloticase is recommended for patients with gout for whom xanthine oxidase inhibitor treatment, uricosurics, and other interventions have failed to achieve the serum uric acid target, and who continue to have frequent gout flares or who have non-resolving subcutaneous tophi.

Krystexxa (pegloticase) will be considered for coverage when the following criteria are met:

CareSource considers Krystexxa (pegloticase) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off- Label policy.

DATE	ACTION/DESCRIPTION
04/06/2021	New policy for Krystexxa (pegloticase) created.
07/28/2022	Transferred to new template. Updated and added references. Removed nephrology, podiatry specialists. Corrected sUC to sUA. Added QL. Added must be given with methotrexate (new labeling). Added not to be used with other urate lowering drugs. Added example dosing to first line allopurinol.

References:

1. Krystexxa [package insert]. Dublin, Ireland; Horizon Therapeutics Ireland DAC; 2022.
2. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout [published correction appears in Arthritis Care Res (Hoboken). 2020 Aug;72(8):1187] [published correction appears in Arthritis Care Res (Hoboken). 2021 Mar;73(3):458]. *Arthritis Care Res (Hoboken)*. 2020;72(6):744-760.
3. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis*. 2017;76(1):29-42.